Literature DB >> 9371613

The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection.

J D Lifson1, M A Nowak, S Goldstein, J L Rossio, A Kinter, G Vasquez, T A Wiltrout, C Brown, D Schneider, L Wahl, A L Lloyd, J Williams, W R Elkins, A S Fauci, V M Hirsch.   

Abstract

Different patterns of viral replication correlate with the natural history of disease progression in humans and macaques infected with human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV), respectively. However, the viral and host factors influencing these patterns of viral replication in vivo are poorly understood. We intensively studied viral replication in macaques receiving identical inocula of SIV. Marked differences in viral replication patterns were apparent within the first week following inoculation, a time prior to the development of measurable specific immune effector responses to viral antigens. Plasma viral RNA levels measured on day 7 postinoculation correlated with levels measured in the postacute phase of infection. Differences in the susceptibility of host cells from different animals to in vitro SIV infection correlated with the permissiveness of the animals for early in vivo viral replication and hence with the postacute set point level of plasma viremia. These results suggest that host factors that exert their effects prior to full development of specific immune responses are critical in establishing the in vivo viral replication pattern and associated clinical course in subjects infected with SIV and, by extension, with HIV-1.

Entities:  

Mesh:

Year:  1997        PMID: 9371613      PMCID: PMC230257     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

1.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

Authors:  M A Nowak; A L Lloyd; G M Vasquez; T A Wiltrout; L M Wahl; N Bischofberger; J Williams; A Kinter; A S Fauci; V M Hirsch; J D Lifson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 2.  The SIVmac specific cytotoxic T lymphocyte response in the acutely infected rhesus monkey.

Authors:  N L Letvin; K A Reimann; Y Yasutomi; D J Ringler; H Yamamoto
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

3.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

4.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  MHC class I and non-MHC-linked capacity for generating an anti-viral CTL response determines susceptibility to CTL exhaustion and establishment of virus persistence in mice.

Authors:  D Moskophidis; F Lechner; H Hengartner; R M Zinkernagel
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

6.  Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV.

Authors:  G Pantaleo; J F Demarest; H Soudeyns; C Graziosi; F Denis; J W Adelsberger; P Borrow; M S Saag; G M Shaw; R P Sekaly
Journal:  Nature       Date:  1994-08-11       Impact factor: 49.962

7.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Variable course of primary simian immunodeficiency virus infection in lymph nodes: relation to disease progression.

Authors:  L Chakrabarti; M C Cumont; L Montagnier; B Hurtrel
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

Review 9.  T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS.

Authors:  R M Zinkernagel; H Hengartner
Journal:  Immunol Today       Date:  1994-06

10.  Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques.

Authors:  K A Reimann; K Tenner-Racz; P Racz; D C Montefiori; Y Yasutomi; W Lin; B J Ransil; N L Letvin
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  117 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Biologic studies of chimeras of highly and moderately virulent molecular clones of simian immunodeficiency virus SIVsmPBj suggest a critical role for envelope in acute AIDS virus pathogenesis.

Authors:  M Haddrick; C R Brown; R Plishka; A Buckler-White; V M Hirsch; H Ginsberg
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  Immune response and virus population composition: HIV as a case study.

Authors:  Gal Almogy; Netta Cohen; Sabine Stöcker; Lewi Stone
Journal:  Proc Biol Sci       Date:  2002-04-22       Impact factor: 5.349

4.  Contribution of peaks of virus load to simian immunodeficiency virus pathogenesis.

Authors:  Roland R Regoes; Silvija I Staprans; Mark B Feinberg; Sebastian Bonhoeffer
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

5.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost.

Authors:  R J Gorelick; R E Benveniste; J D Lifson; J L Yovandich; W R Morton; L Kuller; B M Flynn; B A Fisher; J L Rossio; M Piatak; J W Bess; L E Henderson; L O Arthur
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination.

Authors:  Lei Zhang; Ruy M Ribeiro; John R Mascola; Mark G Lewis; Gabriela Stiegler; Hermann Katinger; Alan S Perelson; Miles P Davenport
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx.

Authors:  Richard Onanga; Christopher Kornfeld; Ivona Pandrea; Jerome Estaquier; Sandrine Souquière; Pierre Rouquet; Virginie Poaty Mavoungou; Olivier Bourry; Souleymane M'Boup; Françoise Barré-Sinoussi; François Simon; Cristian Apetrei; Pierre Roques; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.